AUTOIMMUN TIREOIDIT VA VON WILLEBRAND OMILI O‘RTASIDAGI BOG‘LIQLIK VA UNING ENDOTELIAL DISFUNKTSIYANI RIVOJLANISHIDAGI ROLI
##article.subject##:
autoimmun tireoidit, von Willebrand omili, endotelial disfunktsiya, gipotireoz, gipertireoz, yurak-qon tomir kasalliklari##article.abstract##
Kirish: Autoimmun tireoidit (AIT) eng ko‘p uchraydigan endokrin buzilishlardan biri bo‘lib, ko‘pincha gipotireozga olib keladi. Kasallik keng tarqalgan bo‘lib, asosan ayollar kasallanadi. AIT patogenezini o‘rganishda katta yutuqlarga erishilganiga qaramay, kasallik rivojlanishining mexanizmlari va uning organizmning boshqa tizimlariga, jumladan, yurak-qon tomir tizimiga ta’siri bilan bog‘liq muammolar oxirigacha hal qilinmagan holda qolmoqda. Muhim jihat AIT bilan kasallangan bemorlarda gemostaz tizimini, xususan, zarar ko‘rgan endoteliy yuzalariga trombotsitlar yopishishini va VIII faktorni barqarorlashtirishda muhim rol o‘ynaydigan von Willebrand omili (vWF) darajasini baholashdir. Von Willebrand omili endotelial disfunktsiyaning belgisi bo‘lib, o‘z navbatida, yurak-qon tomir kasalliklarining erta prediktori hisoblanadi. vWF darajasidagi o‘zgarishlar yallig‘lanish jarayonlari va gemostaz tizimidagi buzilishlarning mavjudligini ko‘rsatishi mumkin, bu esa uni AITda muhim tadqiqot ob’ekti qiladi.
Tadqiqot maqsadlari: AITning turli fazalaridagi bemorlarda von Willebrand omili darajasini baholash va uning endotelial disfunktsiyani rivojlanishidagi rolini o‘rganish.
Tadqiqot materiallari va usullar: Tadqiqotga AIT bilan og‘rigan 113 bemor va nazorat guruhi sifatida 94 sog‘lom shaxs kiritildi. Von Willebrand omili darajalari immunologik usullar yordamida aniqlangan. Ma’lumotlar tahlili kasallik fazasiga qarab von Willebrand omili darajasidagi o‘zgarishlarni aniqlash uchun o‘tkazildi.
Tadqiqot natijalari: Eutireozdagi bemorlarda von Willebrand omili darajasi (105,40±23,44%) nazorat guruhiga (106,74±24,85%) o‘xshash edi. Subklinik gipotireozda von Willebrand omili darajasi 93,75±26,80% gacha o‘rtacha kamaydi, bu gemostaz tizimida boshlang‘ich o‘zgarishlarni ko‘rsatadi. Manifest gipotireozda von Willebrand omili darajasining 40,38±7,09% gacha sezilarli darajada pasayishi bilan kechdi, bu esa aniq ifodalangan gemostatik buzilishlarni ko‘rsatadi. Gipertireozda von Willebrand omili darajasi keskin oshib, 172,11±15,94% ni tashkil etdi, bu tromboembolik asoratlar xavfining oshishi bilan bog‘liq edi.
Xulosa: Olingan ma’lumotlar AIT bilan kasallangan bemorlarda gemostaz buzilishlarini o‘z vaqtida aniqlash va tuzatish uchun von Willebrand omili darajasini muntazam kuzatib borish muhimligini ta’kidlaydi. Muntazam kuzatuv va davolashni moslashtirish bemorlarning prognozi va hayot sifatini yaxshilashi mumkin.
Библиографические ссылки
Исмаилов С.И., Гулямова Х.Р., Ахмедова Ш.У., and Максутова Н.Н.. "Взаимосвязь сахарного диабета и тиреоидной патологии (обзор литературы)" Международный эндокринологический журнал, no. 3 (67), 2015, pp. 148-15
Муратова Ш.Т. Клинико-метаболические и психологические особенности у детей и подростков с тиреотоксикозом: совершенствование методов диагностики и лечения, Автореферат диссертации Доктора Наук (DSc) по медицинским наукам, 2024, стр. 35
Villar, H., et al. "Effects of Thyroid Hormone Therapy on Symptoms, Quality of Life, and Biochemical Markers in Patients with Subclinical Hypothyroidism: A Meta-Analysis." JAMA, vol. 311, no. 10, 2014, pp. 1035-1045.
Ochs, N., et al. "Subclinical Hypothyroidism and the Risk of Coronary Heart Disease and Mortality." JAMA, vol. 295, no. 9, 2006, pp. 1033-1041.
Rodondi, N., et al. "Subclinical Hypothyroidism and the Risk of Heart Failure, Other Cardiovascular Events, and Death." Archives of Internal Medicine, vol. 165, no. 21, 2005, pp. 2460-2466.
Furchgott, R. F., and Zawadzki, J. V. "The Obligatory Role of Endothelial Cells in the Relaxation of Arterial Smooth Muscle by Acetylcholine." Nature, vol. 288, 1980, pp. 373-376.
Vanderpump, M. P. "The Epidemiology of Thyroid Disease." British Medical Bulletin, vol. 99, no. 1, 2011, pp. 39-51.
Roberts, C. G., and Ladenson, P. W. "Hypothyroidism." The Lancet, vol. 379, no. 9821, 2012, pp. 1390-1402.
Taylor, P. N., et al. "Global Epidemiology of Hyperthyroidism and Hypothyroidism." Nature Reviews Endocrinology, vol. 14, no. 5, 2018, pp. 301-316.
Biondi, B., and Cooper, D. S. "The Clinical Significance of Subclinical Thyroid Dysfunction." Endocrine Reviews, vol. 29, no. 1, 2008, pp. 76-131.
Pearce, S. H. S., et al. "2013 ETA Guideline: Management of Subclinical Hypothyroidism." European Thyroid Journal, vol. 2, no. 4, 2013, pp. 215-228.
Kahapola-Arachchige, K. M., et al. "Serum Selenium in Women with Newly Diagnosed Thyroid Disease in the UK." Nutrients, vol. 10, no. 3, 2018, p. 308.
